Progesterone for the prevention of preterm birth among women at increased risk: A systematic review and meta-analysis of randomized controlled trials

American Journal of Obstetrics and Gynecology

Volumn 194, Issue 5, 2006, Pages 1234-1242

  Mackenzie, Roberta ^a   Walker, Mark ^b   Armson, Anthony ^c   Hannah, Mary E ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Preterm birth; Progestational agent; Randomized controlled trial; Systematic review

Indexed keywords

CORTICOSTEROID; GESTAGEN; HYDROXYPROGESTERONE CAPROATE; PROGESTERONE; UTERUS SPASMOLYTIC AGENT;

ARTICLE; BRAIN HEMORRHAGE; CLINICAL TRIAL; COCHRANE LIBRARY; CONGENITAL MALFORMATION; EMBASE; FOLLOW UP; HUMAN; LUNG DYSPLASIA; MEDLINE; META ANALYSIS; NECROTIZING ENTEROCOLITIS; NEWBORN MORBIDITY; PATENT DUCTUS ARTERIOSUS; PERINATAL DEATH; PERINATAL MORTALITY; PREGNANCY; PREMATURE LABOR; PREMATURITY; PRIORITY JOURNAL; RESPIRATORY DISTRESS SYNDROME; RESPIRATORY TRACT DISEASE; RETROLENTAL FIBROPLASIA; RISK; RISK FACTOR; SEPSIS; SIDE EFFECT; SPONTANEOUS ABORTION; SYSTEMATIC REVIEW; UTERINE CERVIX CERCLAGE;

DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; OBSTETRIC LABOR, PREMATURE; PREGNANCY; PREGNANCY TRIMESTER, SECOND; PROGESTERONE; PROGESTINS; RANDOMIZED CONTROLLED TRIALS; RISK; RISK FACTORS;

EID: 33646117981     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2005.06.049     Document Type: Article

References (76)

1. Kramer M.S., Demissie K., Yang H., Platt R.W., Sauve R., and Liston R. The contribution of mild and moderate preterm birth to infant mortality. JAMA 284 (2000) 843-849
2. Wood N.S., Marlow N., Costeloe K., Gibson A.T., and Wilkinson A.R. Neurologic and developmental disability after extremely preterm birth. N Engl J Med 343 (2000) 378-384
3. Magowan B.A., Bain M., Juszczak E., and McInneny K. Neonatal mortality amongst Scottish preterm singleton births (1985-1994). BJOG 105 (1998) 1005-1010
4. Wigton T.R., Tamura R.K., Wickstrom E., Atkins V., Deddish R., and Socol M.L. Neonatal morbidity after preterm delivery in the presence of documented lung maturity. Am J Obstet Gynecol 169 (1993) 951-955
5. Copper R.L., Goldenberg R.L., Creasy R.K., Du Bard M.B., Davis R.O., Entman S.S., et al. A multicenter study of preterm birth weight and gestational age-specific neonatal mortality. Am J Obstet Gynecol 168 (1993) 78-84
6. Rettwitz-Volk W., Tran T.M., and Veldman A. Cerebral morbidity in preterm twins. J Matern Fetal Neonatal Med 13 (2003) 218-223
7. Gilbert W.M., Nesbitt T.S., and Danielsen B. The cost of prematurity: quantification by gestational age and birth weight. Obstet Gynecol 102 (2003) 488-492
8. Petrou S., Mehta Z., Hockley C., Cook-Mozaffari P., Henderson J., and Goldacre M. The impact of preterm birth on hospital admissions and costs during the first 5 years of life. Pediatrics 112 (2003) 1290-1297
9. Joseph K.S., Kramer M.S., Marcoux S., Ohlsson A., Wen S.W., Allen A., et al. Determinants of preterm birth rates in Canada from 1981 through 1983 and from 1992 through 1994. N Engl J Med 339 (1998) 1434-1439
10. Health Canada. Canadian Perinatal Surveillance System. Canadian Perinatal Health Report 2003. Chapter 4;73-6. Available at: http://www.hc-sc.gc.ca/pphb-dgspsp/rhs-ssg/index.html. Accessed July 10, 2005.
11. Craig E.D., Thompson J.M., and Mitchell E.A. Socioeconomic status and preterm birth: New Zealand trends, 1980 to 1999. Arch Dis Child Fetal Neonatal Ed 86 (2002) F142-F146
12. Meis P.J., Goldenberg R.L., Mercer B.M., Iams J.D., Moawad A.H., Miodovnik M., et al. The preterm birth prediction study: risk factors for indicated preterm births. Am J Obstet Gynecol 178 (1998) 562-567
13. Garfield R.E., Kannan M.S., and Daniel E.E. Gap junction formation in myometrium: control by estrogens, progesterone, and prostaglandins. Am J Physiol 238 (1980) C81-C89
14. Allen W.M., and Reynolds S.R.M. Physiology of the corpus luteum: the comparative actions of crystalline progestin and crude progestin on uterine motility in unanesthetized rabbits. Am J Obstet Gynecol 30 (1935) 309-318
15. Csapo A.I., Pulkkinen M.O., and Wiest W.G. Effects of luteectomy and progesterone replacement therapy in early pregnant patients. Am J Obstet Gynecol 115 (1973) 759-765
16. Whitely J.L., Hartmann P.E., Willcox D.L., Bryant-Greenwood G.D., and Greenwood F.C. Initiation of parturition and lactation in the sow: effects of delaying parturition with medroxyprogesterone acetate. J Endocrinol 124 (1990) 475-484
17. Papiernik E. Double blind study of an agent to prevent preterm delivery among women at increased risk. [in French]. Edition Schering, Serie IV, fiche 3 (1970) 65-68
18. Johnson J.W., Austin K.L., Jones G.S., Davis G.H., and King T.M. Efficacy of 17alpha-hydroxyprogesterone caproate in the prevention of premature labor. N Engl J Med 293 (1975) 675-680
19. Meis P.J., Klebanoff M., Thom E., Dombrowski M.P., Sibai B., Moawad A.H., et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 348 (2003) 2379-2385
20. Creasy R.K., Gummer B.A., and Liggins G.C. System for predicting spontaneous preterm birth. Obstet Gynecol 55 (1980) 692-695
21. DerSimonian R., and Laird N. Meta-analysis in clinical trials. Control Clin Trials 7 (1986) 177-188
22. Cibils L.A., and Zuspan F.P. Pharmacologic control of premature labor. Clin Obstet Gynecol 16 (1973) 199-212
23. Cope E., and Emelife E.C. Habitual abortion treated with 17α-hydroxyprogesterone capronate. J Obstet Gynaecol Br Commonw 72 (1965) 1035-1037
24. Creasy R.K. Preterm birth prevention: where are we?. Am J Obstet Gynecol 168 (1993) 1223-1230
25. Daya S. Efficacy of progesterone support for pregnancy in women with recurrent miscarriage: a meta-analysis of controlled trials. BJOG 96 (1989) 275-280
26. Fuchs A.-R., and Fuchs F. Mechanism and prevention of preterm birth. Prog Clin Biol Res 163B (1985) 223-230
27. Gazaway P., and Mullins C.L. Prevention of preterm labor and premature rupture of the membranes. Clin Obstet Gynecol 29 (1986) 835-849
28. Gilstrap III L.C., and Brown C.E.L. Prevention and treatment of preterm labor in twins. Clin Perinatol 15 (1988) 71-77
29. Goldstein P., Berrier J., Rosen S., Sacks H.S., and Chalmers T.C. A meta-analysis of randomized control trials of progestational agents in pregnancy. BJOG 96 (1989) 265-274
30. Johnson J.W.C., Lee P.A., Zachary A.S., Calhoun S., and Migeon C.J. High-risk prematurity-progestin treatment and steroid studies. Obstet Gynecol 54 (1979) 412-418
31. Kierse M.J.N.C. Progestogen administration in pregnancy may prevent preterm delivery. BJOG 97 (1990) 149-154
32. Hill L.M., Johnson C.E., and Lee R.A. Prophylactic use of hydroxyprogesterone caproate in abdominal surgery during pregnancy: a retrospective evaluation. Obstet Gynecol 46 (1975) 287-290
33. Sherman A.I. Hormonal therapy for control of the incompetent os of pregnancy. Obstet Gynecol 28 (1966) 198-205
34. Spong C.Y. Recent developments in preventing recurrent preterm birth. Obstet Gynecol 101 (2003) 1153-1154
35. Suvonnakote T. Prevention of pre-term labour with progesterone. J Med Assoc Thailand 69 (1986) 538-542
36. Zuspan F.P. Premature labor: its management and therapy. J Reprod Med 9 (1972) 93-118
37. Varma T.R., and Morsman J. Evaluation of the use of Proluton-Depot (hydroxyprogesterone hexanoate) in early pregnancy. Int J Gynaecol Obstet 20 (1982) 13-17
38. Nesbitt R.E.L., Aubry R.H., Goldberg E.M., and Jacobs R.D. Correlated hormone excretion patterns and cytohormone variations in normal and complicated pregnancies; influence of administration of ovarian steroids or placebo in relation to outcome of pregnancy. Am J Obstet Gynecol 93 (1965) 702-719
39. Csapo A.I., Pohanka O., and Kaihola H.L. Progesterone deficiency and premature labour. BMJ 1 (1974) 137-140
40. Daya S., Ward S., and Burrows E. Progesterone profiles in luteal phase defect cycles and outcome of progesterone treatment in patients with recurrent spontaneous abortion. Am J Obstet Gynecol 158 (1988) 225-232
41. Franczak J., Jagiello-Wójtowicz E., and Kamińska H. The estimation of progesterone in preterm delivery. Ann Univ Mariae Curie Sklodowska [Med] 50 (1995) 157-160
42. Iams J.D., Newman R.B., Thom E.A., Goldenberg R.L., Mueller-Heubach E., Moawad A., et al. Frequency of uterine contractions and the risk of spontaneous preterm delivery. N Engl J Med 346 (2002) 250-255
43. Jamain M., and Grenet C. Utilisation de la 6-déhydro-rétroprogestérone en obstétrique. Indications, resultats. Bulletin de la Federation des Societes de Gynecologie et d'Obstetrique de Langue Francaise 21 (1969) 26-31
44. Kauppila A., Hartikainen-Sorri A.-L., Jänne O., Tuimala R., and Järvinen P.A. Suppression of threatened premature labor by administration of cortisol and 17α-hydroxyprogesterone caproate: a comparison with ritodrine. Am J Obstet Gynecol 138 (1980) 404-408
45. Reifenstein E.C. Clinical use of 17α-hydroxyprogesterone 17-n-caproate in habitual abortion. Ann NY Acad Sci 71 (1958) 762-786
46. Raja R.L.T., Anderson A.B.M., and Turnbull A.C. Endocrine changes in premature labour. BMJ 4 (1974) 67-71
47. Wentz A.C. Progesterone therapy of the inadequate luteal phase. Curr Probl Obstet Gynecol 6 (1982) 5-49
48. Corrado F., Dugo C., Cannata M.L., Di Bartolo M., Scilipoti A., and Carlo Stella N. A randomised trial of progesterone prophylaxis after midtrimester amniocentesis. Eur J Obstet Gynecol Reprod Biol 100 (2002) 196-198
49. Hauth J.C., Gilstrap III L.C., Brekken A.L., and Hauth J.M. The effect of 17α-hydroxyprogesterone caproate on pregnancy outcome in an active-duty military population. Am J Obstet Gynecol 146 (1983) 187-190
50. Brenner W.E., and Hendricks C.H. Effect of medroxyprogesterone acetate upon the duration and characteristics of human gestation and labor. Am J Obstet Gynecol 83 (1962) 1094-1098
51. Dalton K. Controlled trials in the prophylactic value of progesterone in the treatment of pre-eclamptic toxaemia. J Obstet Gynaecol Br Commonw 69 (1962) 463-468
52. Benifla J.L., Dumont M., Levardon M., Foucher E., Cadiot G., Crenn-Hebert C., et al. Effets de la progesterone naturelle micronisee sur le foie au cours du troisieme trimestre de la grossesse. Contracept Fertil Sex 25 (1997) 165-169
53. Erny R., Pigne A., Prouvost C., Gamerre M., Malet C., Serment H., et al. The effects of oral administration of progesterone for premature labor. Am J Obstet Gynecol 154 (1986) 525-529
54. Fuchs F., and Stakemann G. Treatment of threatened premature labor with large doses of progesterone. Am J Obstet Gynecol 79 (1960) 172-176
55. Gerhard I., Gwinner B., Eggert-Kruse W., and Runnebaum B. Double-blind controlled trial of progesterone substitution in threatened abortion. Biol Res Pregnancy Perinatol 8 (1987) 26-34
56. Govaerts-Videtzky M., Martin L., and Hubinont P.O. A double-blind study of progestogen treatment in spontaneous abortion. J Obstet Gynaecol Br Commonw 72 (1965) 1034
57. Moller K.J.A., and Fuchs F. Double-blind controlled trial of 6-methyl, 17-acetoprogesterone in threatened abortion. J Obstet Gynaecol Br Commonw 72 (1965) 1042-1044
58. Noblot G., Audra P., Dargent D., Faguer B., and Mellier G. The use of micronized progesterone in the treatment of menace of preterm delivery. Eur J Obstet Gynecol Reprod Biol 40 (1991) 203-209
59. Sondergaard F., Ottesen B., Detlefsen G.U., Schierup L., Pedersen S.C., and Lebech P.E. Traitement par la progestérone des menaces d'accouchement prématuré avec taux bas de progesterone plasmatique. Contracept Fertil Sex 13 (1985) 1227-1231
60. Souka A.R., Osman M., Sibaie F., and Einen M.A. Therapeutic value of indomethacin in threatened abortion. Prostaglandins 19 (1980) 457-460
61. Tognoni G., Ferrario L., Inzalaco M., and Crosignani P.G. Progestagens in threatened abortion. Lancet 316 (1980) 1242-1243
62. Swyer G.I.M., and Daley D. Progesterone implantation in habitual abortion. BMJ I (1953) 1073-1077
63. Mavroudis K., Petsos P., Zulkifli Z., Cantrill J., Shingles C., Newman M., et al. Trial of 17-hydroxyprogesterone caproate (Proluton Depot) in women with long-standing infertility; failure of estrogen positive feedback the following cycle. Gynecol Endocrinol 1 (1987) 177-193
64. Hartikainen-Sorri A.-L., Kauppila A., and Tuimala R. Inefficacy of 17 alpha-hydroxprogesterone caproate in the prevention of prematurity in twin pregnancy. Obstet Gynecol 56 (1980) 692-695
65. Goldzieher J.W. Double blind trial of a progestin in habitual abortion. JAMA 188 (1964) 651-654
66. Klopper A., and MacNaughton M. Hormones in recurrent abortion. J Obstet Gynaecol Br Commonw 72 (1965) 1022-1028
67. Shearman R.P., and Garrett W.J. Double-blind study of effect of 17-hydroxyprogesterone caproate on abortion rate. BMJ 5326 (1963) 292-295
68. Yemini M., Borenstein R., Dreazen E., Apelman Z., Mogilner B.M., Kessler I., et al. Prevention of premature labor by 17α-hydroxyprogesterone caproate. Am J Obstet Gynecol 151 (1985) 574-577
69. LeVine L. Habitual abortion: a controlled study of progestational therapy. West J Surg Obstet Gynecol 72 (1964) 30-36
70. Turner S.J., Mizock G.B., and Feldman G.L. Prolonged gynecologic and endocrine manifestations subsequent to administration of medroxyprogesterone acetate during pregnancy. Am J Obstet Gynecol 95 (1996) 222-227
71. Da Fonseca E.B., Bittar R.E., Carvalho M.H.B., and Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol 188 (2003) 419-424
72. Herbst A.L., Ulfelder H., and Poskanzer D.C. Association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med 284 (1971) 878-881
73. Iams J.D., Goldenberg R.L., Meis P.J., Mercer B.M., Moawad A., Das A., et al., the NICHD MFM Units Network. The length of the cervix and the risk of spontaneous premature delivery. N Engl J Med 334 (1996) 567-572
74. Kahn B., Lumey L.H., Zybert P.A., Lorenz J.M., Cleary-Goldman J., D'Alton M.E., et al. Prospective risk of fetal death in singleton, twin, and triplet gestations: implications for practice. Obstet Gynecol 102 (2003) 685-692
75. Centers for Disease Control and Prevention. Epi Info 6. A word processing, database and statistics program for public health (1996), CDC, Atlanta, GA
76. Sanchez-Ramos L., Kaunitz A.M., and Delke I. Progestational agents to prevent preterm birth: a meta-analysis of randomized controlled trials. Obstet Gynecol 105 (2005) 273-279